Media Center Investor Relations Overview Investor News Press Releases Company Statements Media Kit Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Press Releases Year All2026202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002 Mar 09, 2026 Ionis announces changes to Board of Directors Feb 27, 2026 Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting Feb 26, 2026 Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) Feb 25, 2026 Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs Feb 19, 2026 Ionis to present at upcoming investor conferences Feb 17, 2026 Ionis updates time for fourth quarter and full year 2025 financial results webcast Feb 11, 2026 Ionis to hold fourth quarter and full year 2025 financial results webcast Jan 21, 2026 DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) Jan 12, 2026 Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts Jan 07, 2026 Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B Jan 06, 2026 Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
Year All2026202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002 Mar 09, 2026 Ionis announces changes to Board of Directors Feb 27, 2026 Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting Feb 26, 2026 Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) Feb 25, 2026 Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs Feb 19, 2026 Ionis to present at upcoming investor conferences Feb 17, 2026 Ionis updates time for fourth quarter and full year 2025 financial results webcast Feb 11, 2026 Ionis to hold fourth quarter and full year 2025 financial results webcast Jan 21, 2026 DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) Jan 12, 2026 Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts Jan 07, 2026 Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B Jan 06, 2026 Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
Feb 27, 2026 Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Feb 26, 2026 Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Feb 25, 2026 Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Jan 12, 2026 Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Jan 07, 2026 Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
